399 related articles for article (PubMed ID: 27055211)
21. Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis.
Li JX; Tsai YY; Lai CT; Li YL; Wu YH; Chiang CC
J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078948
[TBL] [Abstract][Full Text] [Related]
22. Results of a Multicenter, Randomized, Double-Masked, Placebo-Controlled Clinical Study of the Efficacy and Safety of Visomitin Eye Drops in Patients with Dry Eye Syndrome.
Brzheskiy VV; Efimova EL; Vorontsova TN; Alekseev VN; Gusarevich OG; Shaidurova KN; Ryabtseva AA; Andryukhina OM; Kamenskikh TG; Sumarokova ES; Miljudin ES; Egorov EA; Lebedev OI; Surov AV; Korol AR; Nasinnyk IO; Bezditko PA; Muzhychuk OP; Vygodin VA; Yani EV; Savchenko AY; Karger EM; Fedorkin ON; Mironov AN; Ostapenko V; Popeko NA; Skulachev VP; Skulachev MV
Adv Ther; 2015 Dec; 32(12):1263-79. PubMed ID: 26660938
[TBL] [Abstract][Full Text] [Related]
23. Clinical Outcomes of Lifitegrast 5% Ophthalmic Solution in the Treatment of Dry Eye Disease.
Tong AY; Passi SF; Gupta PK
Eye Contact Lens; 2020 Jan; 46 Suppl 1():S20-S24. PubMed ID: 30985492
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group.
Stevenson D; Tauber J; Reis BL
Ophthalmology; 2000 May; 107(5):967-74. PubMed ID: 10811092
[TBL] [Abstract][Full Text] [Related]
25. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation.
Donnenfeld ED; Holland EJ; Stewart RH; Gow JA; Grillone LR;
Ophthalmology; 2007 Sep; 114(9):1653-62. PubMed ID: 17445902
[TBL] [Abstract][Full Text] [Related]
26. A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye.
Kinoshita S; Oshiden K; Awamura S; Suzuki H; Nakamichi N; Yokoi N;
Ophthalmology; 2013 Jun; 120(6):1158-65. PubMed ID: 23490326
[TBL] [Abstract][Full Text] [Related]
27. Lifitegrast: First LFA-1/ICAM-1 antagonist for treatment of dry eye disease.
Paton DM
Drugs Today (Barc); 2016 Sep; 52(9):485-493. PubMed ID: 27883115
[TBL] [Abstract][Full Text] [Related]
28. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye.
Tauber J; Davitt WF; Bokosky JE; Nichols KK; Yerxa BR; Schaberg AE; LaVange LM; Mills-Wilson MC; Kellerman DJ
Cornea; 2004 Nov; 23(8):784-92. PubMed ID: 15502479
[TBL] [Abstract][Full Text] [Related]
29. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
[TBL] [Abstract][Full Text] [Related]
30. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%.
Sheppard JD; Donnenfeld ED; Holland EJ; Slonim CB; Solomon R; Solomon KD; McDonald MB; Perry HD; Lane SS; Pflugfelder SC; Samudre SS
Eye Contact Lens; 2014 Sep; 40(5):289-96. PubMed ID: 25083776
[TBL] [Abstract][Full Text] [Related]
31. Ocular Distribution and Pharmacokinetics of Lifitegrast in Pigmented Rabbits and Mass Balance in Beagle Dogs.
Chung JK; Spencer E; Hunt M; McCauley T; Welty D
J Ocul Pharmacol Ther; 2018; 34(1-2):224-232. PubMed ID: 29267138
[TBL] [Abstract][Full Text] [Related]
32. Randomized, Multicenter, Double-Blind Study of the Safety and Efficacy of 1%D-3-Hydroxybutyrate eye drops for Dry Eye Disease.
Kawakita T; Uchino M; Fukagawa K; Yoshino K; Shimazaki S; Toda I; Tanaka M; Arai H; Sakatani K; Hata S; Okano T; Tsubota K
Sci Rep; 2016 Feb; 6():20855. PubMed ID: 26865350
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of topical azithromycin ophthalmic solution 1.0% in the treatment of contact lens-related dry eye.
Nichols JJ; Bickle KM; Zink RC; Schiewe MD; Haque RM; Nichols KK
Eye Contact Lens; 2012 Mar; 38(2):73-9. PubMed ID: 22157392
[TBL] [Abstract][Full Text] [Related]
34. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
Liew SH; Nichols KK; Klamerus KJ; Li JZ; Zhang M; Foulks GN
Ophthalmology; 2012 Jul; 119(7):1328-35. PubMed ID: 22525048
[TBL] [Abstract][Full Text] [Related]
35. Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease--A Prospective, Multicenter Noninterventional Study.
Steven P; Scherer D; Krösser S; Beckert M; Cursiefen C; Kaercher T
J Ocul Pharmacol Ther; 2015 Oct; 31(8):498-503. PubMed ID: 26296040
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of the Long-Acting Diquafosol Ophthalmic Solution DE-089C in Patients with Dry Eye: A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study.
Hori Y; Oka K; Inai M
Adv Ther; 2022 Aug; 39(8):3654-3667. PubMed ID: 35716319
[TBL] [Abstract][Full Text] [Related]
37. Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease.
Chhabra S; Jerkins JH; Conto JE; Zellner K; Shah NN; Hari PN; Hamadani M
Leuk Lymphoma; 2020 Apr; 61(4):869-874. PubMed ID: 31762357
[TBL] [Abstract][Full Text] [Related]
38. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.
Karpecki P; Depaolis M; Hunter JA; White EM; Rigel L; Brunner LS; Usner DW; Paterno MR; Comstock TL
Clin Ther; 2009 Mar; 31(3):514-26. PubMed ID: 19393842
[TBL] [Abstract][Full Text] [Related]
39. Demonstration of efficacy in the treatment of dry eye disease with 0.18% sodium hyaluronate ophthalmic solution (vismed, rejena).
Vogel R; Crockett RS; Oden N; Laliberte TW; Molina L;
Am J Ophthalmol; 2010 Apr; 149(4):594-601. PubMed ID: 20346777
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of Sodium Hyaluronate/chondroitin Sulfate Preservative-free Ophthalmic Solution in the Treatment of Dry Eye: A Clinical Trial.
Belalcázar-Rey S; Sánchez Huerta V; Ochoa-Tabares JC; Altamirano Vallejo S; Soto-Gómez A; Suárez-Velasco R; García-Félix F; Baiza-Durán L; Olvera-Montaño O; Muñoz-Villegas P
Curr Eye Res; 2021 Jul; 46(7):919-929. PubMed ID: 33289602
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
